AHAndrea Jazel Rodríguez Herrera

Andrea Jazel Rodríguez Herrera

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andrea Jazel Rodríguez Herrera has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Integrated predictive modeling for fibrotic progression in fibrosing interstitial lung diseases

    by Andrea Jazel Rodríguez Herrera, Sabrina Setembre Batah, Danilo Tadao Wada, Marcel Koenigkam Santos, Tales Rubens de Nadai, Andrea Antunes Cetlin, Alexandre Todorovic Fabro

    Background: Fibrosing interstitial lung diseases (ILDs) represent a heterogeneous group of disorders characterized by progressive pulmonary fibrosis, functional decline, and increased mortality. Early identification of patients with a progressive phenotype remains a major clinical challenge, particularly because the true onset of disease prior to diagnosis is often unknown. In this setting, quantitative predictive modeling approaches have emerged as promising tools to provide insight into the natural history of fibrosing ILDs. Objective: To develop a temporal predictive model of disease progression based on clinical and functional variables (FVC, DLCO, age, sex, and time). Methods: Fifty patients who underwent lung biopsy between 2002 and 2019 were included after multidisciplinary discussion. Generalized Additive Mixed Models (GAMMs) were applied to describe FVC trajectories and retrospectively estimate disease duration. Model performance was evaluated through graphical diagnostics, cross-validation, and calculation of R², REML, MSE, and RMSE across all adjustment stages. Results: Time and clinical covariates (sex, age, DLCO) significantly influenced FVC progression. Model 1 and Model 2 represented the most parsimonious and the most comprehensive approaches, respectively, both showing consistent predictive performance after cross-validation. Conclusion: Additive mixed modeling allowed the estimation of disease duration and the precise description of functional progression in Fibrosing ILD underscoring its potential as a tool to support earlier diagnosis and prognostic classification (FAPESP 22/02821-0, 23/10186-6).

  • Open Access

    Enhanced Neocollagenesis and Clinical Efficacy of a Novel Regenerative Diluent for Calcium Hydroxyapatite for Facial Rejuvenation: A 90-Day Clinical Trial

    by Valéria Dal Col, Cassiano Marchi, Fábio Fernandes Ribas, Bárbara Barquette Silva da Rosa, Delcio Eustaquio de Paula Júnior, Maria Auxiliadora Dinalli Marchi, Maria Claudia Ferreira Cavalcanti Santos, Tarita Moioli Martins Abdala, Danielle Campos Ito Palhari, Maracelle Do Nascimento Arruda, et al.

    Facial aging is primarily characterized by the loss and disorganization of the dermal extracellular matrix (ECM), particularly collagen. Injectable biostimulators, such as calcium hydroxyapatite (CaHA), represent a vital non-surgical strategy to counteract these changes by inducing neocollagenesis. This 90-day clinical trial was designed to comparatively evaluate the efficacy of a novel regenerative solution (RS) diluent, formulated to potentially enhance the biostimulatory effects of standard CaHA (STIIM product), against a conventional diluent (control) for the treatment of facial laxity. Twenty-one subjects (N = 21) were randomized to receive CaHA diluted with either RS or control formulation. Efficacy was assessed using histological analysis (collagen I area percentage), ultrasound (US) for dermal density, and clinical laxity scoring. Histological analysis, although limited by a small subsample size (N = 3), showed qualitative and exploratory evidence of collagen remodeling in both groups. However, the RS group showed enhanced dermal thickening via US (15% increase vs. 5% control, p-value = 0.012), and improvement in clinical laxity. Furthermore, histological findings, including Picrosirius red staining, indicated that the RS group resulted in qualitatively greater ECM organization and more robust type I collagen fibers compared to the control. The novel regenerative solution is safe and demonstrates enhanced neocollagenesis and clinical efficacy over the conventional formulation, validating its potential as a diluent for CaHA for optimized facial rejuvenation.


  • Open Access

    Pulmonary Hypertension Secondary to Fungal Infections: Underexplored Pathological Links

    by Andrea Jazel Rodríguez-Herrera, Sabrina Setembre Batah, Maria Júlia Faci Do Marco, Carlos Mario González-Zambrano, Luciane Alarcão Dias-Melicio, Alexandre Todorovic Fabro

    Background/Objective: Pulmonary fungal infections are a significant diagnostic challenge, primarily affecting immunocompromised individuals, such as those with HIV, cancer, or organ transplants, and they often lead to substantial morbidity and mortality if untreated. These infections trigger acute inflammatory and immune responses, which may progress to chronic inflammation. This process involves myofibroblast recruitment, the deposition of extracellular matrix, and vascular remodeling, ultimately contributing to pulmonary hypertension. Despite its clinical relevance, pulmonary hypertension secondary to fungal infections remains under-recognized in practice and poorly studied in research. Results/Conclusion: This narrative mini-review explores three key mechanisms underlying vascular remodeling in this context: (1) endothelial injury caused by fungal emboli or autoimmune reactions, (2) direct vascular remodeling during chronic infection driven by inflammation and fibrosis, and (3) distant vascular remodeling post-infection, as seen in granulomatous diseases like paracoccidioidomycosis. Further research and clinical screening for pulmonary hypertension in fungal infections are crucial to improving patient outcomes.